Combination therapy for osteoporosis: considerations and controversy

Area of Science:

• Bone biology and pharmacology
• Clinical trial analysis
• Osteoporosis treatment strategies

Background:

• Combination therapy for osteoporosis involves using two drugs to reduce fracture risk.
• Antiresorber combinations (estrogen + bisphosphonates) increase bone mass more than monotherapy.
• Anabolic agent (parathyroid hormone) and bisphosphonate combinations do not show additive effects.

Purpose of the Study:

• To review the rationale and clinical trial data for osteoporosis combination therapy.
• To evaluate the benefits and drawbacks of using multiple agents for osteoporosis.
• To determine the current recommendation for combination therapy in clinical practice.

Main Methods:

• Literature review of existing clinical trials on osteoporosis combination therapy.
• Analysis of data on bone mass changes and fracture risk reduction.
• Assessment of cost, side effects, and therapy adherence associated with combination treatments.

Main Results:

• Antiresorber combinations enhance bone mass, but additive effects are not seen with anabolic and bisphosphonate combinations.
• No current studies are sufficiently powered to confirm fracture risk reduction with combination therapy.
• Combination therapy is associated with increased costs, potential for more side effects, and reduced adherence.

Conclusions:

• Combination therapy for osteoporosis has not demonstrated a clear fracture reduction benefit over single-agent therapy.
• Increased costs and likely adverse events outweigh the current unproven benefits.
• Combination therapy is not currently recommended for osteoporosis treatment.